Literature DB >> 36163595

Genetic and epigenetic profiling identifies two distinct classes of spinal meningiomas.

Franz L Ricklefs1, Krystian D Fita1, Ulrich Schüller2,3,4, Sven O Eicker5, Malte Mohme1, Christian Mawrin6, Ramin Rahmanzade7, Felix Sahm7, Lasse Dührsen1, Carolin Göbel8,9, Katrin Lamszus1, Manfred Westphal1.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 36163595      PMCID: PMC9547788          DOI: 10.1007/s00401-022-02504-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   15.887


× No keyword cloud information.
Spinal meningiomas account for 1.2–12% of all meningiomas and 25–45% of all spinal tumors. About 20% of intracranial meningiomas and 4.6% of spinal meningiomas recur and require additional treatment. The classification of intracranial meningiomas has evolved considerably in recent years and uses genetic [1, 3, 7] as well as epigenetic parameters [5, 8] in order to more precisely predict the patients’ prognosis and to lay the ground for therapeutic regimens that are adapted to the aggressiveness of a patient’s tumor. Spinal meningiomas are missing in many of the large cohorts that were gathered for molecular profiling of meningiomas and have neither been thoroughly analyzed separately. Therefore, their classification still relies mostly on histopathological findings. We performed genetic and epigenetic profiling of 65 tumor samples from patients with histologically proven spinal meningioma. Clinical features are described in Supplementary Table 1, online resource, and raw data are accessible at GEO under GSE212449. T-distributed Stochastic Neighbor Embedding (t-SNE) analysis of genome-wide DNA methylation data shows that most spinal meningiomas separated from cranial meningiomas and formed two distinct clusters (Fig. 1a, b). Sixteen out of 19 cases in cluster 1 (84%) significantly matched the methylation class “benign-2” [8], while cluster 2 was more heterogeneous with only 5/42 samples reaching a significant match (12%, MSC score > 0.9, Fig. 1c and d, Supplementary Fig. 1a–c, online resource). Of 19 meningiomas in cluster 1, 13 (68%) were of the meningothelial subtype, 12 (63%) occurred in the cervical spine, and 13 (68%) occurred in male patients (Chi-square, p < 0.001, Fig. 1d, Supplementary Fig. 1d–i, online resource). Notably, all cases with verified AKT1 E17K mutations resided in cluster 1, thereby making up the majority of this cluster (8/13 cases analyzed for mutations). NF2 mutations were detected in 24/32 spinal meningiomas (75%) of the second cluster (Supplementary Fig. 1j, online resource), but only in a single tumor in cluster 1. In line with this observation, a hemizygous loss of chromosome 22q was observed in most cluster 2 cases (29/32, 91%), but only in 3/19 cluster 1 cases (16%, p < 0.0001, Fig. 1d and e). Other mutations that may occur in meningiomas [6] were not recurrently found in our cohort (Supplementary Table 1, online resource). Seven spinal tumors showed close association with cranial meningioma of intermediate and malignant methylation subclasses according to t-SNE analysis (Fig. 1b) and did not show a clear association with cluster 1 or 2 in this context. These cases had a particularly high frequency of cytogenetic aberrations (Fig. 1d and e, marked by asterisks). Collectively, these data suggest that spinal meningiomas encompass two major clinically, genetically, and epigenetically distinct tumor groups, which are either localized primarily in the cervical or the thoracic spine. These data are well in line with recently published work [4] and further complement this work by extensive epigenetic characterization of such tumors. Together, such results may, in the end, lead to a more precise and clinically relevant classification of spinal meningiomas.
Fig. 1

Epigenetic and genetic characterization of spinal meningiomas. A cohort of 65 spinal meningiomas (54 tumors newly acquired, 11 tumors from a reference cohort [8]) was analyzed using DNA methylation arrays and panel-based DNA sequencing. a T-stochastic neighbor embedding (T-SNE) of genome-wide DNA methylation profiles of 65 spinal meningiomas combined with a reference cohort of 2,801 CNS tumors [2] after pairwise Pearson correlation, according to [2]. b T-SNE analysis of 65 spinal meningiomas combined with a reference cohort of 480 cranial meningiomas [8]. c Hierarchical clustering of 10,000 CpG positions with the highest SD from the DNA methylation array datasets used in b (Ward’s linkage method, Euclidean distances). d Oncoplot of 65 spinal meningioma with clinical and genetic features. Unsupervised hierarchical clustering of 10,000 CpG positions with highest SD across samples (complete linkage, Euclidean distance). MSC = methylation subclass score, Scores > 0.9 e Genome-wide copy number variation profile of spinal meningioma samples from d based on DNA methylation arrays. Asterisks mark cases that do not belong to the two main clusters according to b and that mostly reveal a high frequency of cytogenetic aberrations

Epigenetic and genetic characterization of spinal meningiomas. A cohort of 65 spinal meningiomas (54 tumors newly acquired, 11 tumors from a reference cohort [8]) was analyzed using DNA methylation arrays and panel-based DNA sequencing. a T-stochastic neighbor embedding (T-SNE) of genome-wide DNA methylation profiles of 65 spinal meningiomas combined with a reference cohort of 2,801 CNS tumors [2] after pairwise Pearson correlation, according to [2]. b T-SNE analysis of 65 spinal meningiomas combined with a reference cohort of 480 cranial meningiomas [8]. c Hierarchical clustering of 10,000 CpG positions with the highest SD from the DNA methylation array datasets used in b (Ward’s linkage method, Euclidean distances). d Oncoplot of 65 spinal meningioma with clinical and genetic features. Unsupervised hierarchical clustering of 10,000 CpG positions with highest SD across samples (complete linkage, Euclidean distance). MSC = methylation subclass score, Scores > 0.9 e Genome-wide copy number variation profile of spinal meningioma samples from d based on DNA methylation arrays. Asterisks mark cases that do not belong to the two main clusters according to b and that mostly reveal a high frequency of cytogenetic aberrations Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 13 kb) Supplementary file2 (TIF 1237 kb) Supplementary file3 (DOCX 51 kb)
  8 in total

1.  DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.

Authors:  Felix Sahm; Daniel Schrimpf; Damian Stichel; David T W Jones; Thomas Hielscher; Sebastian Schefzyk; Konstantin Okonechnikov; Christian Koelsche; David E Reuss; David Capper; Dominik Sturm; Hans-Georg Wirsching; Anna Sophie Berghoff; Peter Baumgarten; Annekathrin Kratz; Kristin Huang; Annika K Wefers; Volker Hovestadt; Martin Sill; Hayley P Ellis; Kathreena M Kurian; Ali Fuat Okuducu; Christine Jungk; Katharina Drueschler; Matthias Schick; Melanie Bewerunge-Hudler; Christian Mawrin; Marcel Seiz-Rosenhagen; Ralf Ketter; Matthias Simon; Manfred Westphal; Katrin Lamszus; Albert Becker; Arend Koch; Jens Schittenhelm; Elisabeth J Rushing; V Peter Collins; Stefanie Brehmer; Lukas Chavez; Michael Platten; Daniel Hänggi; Andreas Unterberg; Werner Paulus; Wolfgang Wick; Stefan M Pfister; Michel Mittelbronn; Matthias Preusser; Christel Herold-Mende; Michael Weller; Andreas von Deimling
Journal:  Lancet Oncol       Date:  2017-03-15       Impact factor: 41.316

2.  Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated.

Authors:  Sybren L N Maas; Damian Stichel; Thomas Hielscher; Philipp Sievers; Anna S Berghoff; Daniel Schrimpf; Martin Sill; Philipp Euskirchen; Christina Blume; Areeba Patel; Helin Dogan; David Reuss; Hildegard Dohmen; Marco Stein; Annekathrin Reinhardt; Abigail K Suwala; Annika K Wefers; Peter Baumgarten; Franz Ricklefs; Elisabeth J Rushing; Melanie Bewerunge-Hudler; Ralf Ketter; Jens Schittenhelm; Zane Jaunmuktane; Severina Leu; Fay E A Greenway; Leslie R Bridges; Timothy Jones; Conor Grady; Jonathan Serrano; John Golfinos; Chandra Sen; Christian Mawrin; Christine Jungk; Daniel Hänggi; Manfred Westphal; Katrin Lamszus; Nima Etminan; Gerhard Jungwirth; Christel Herold-Mende; Andreas Unterberg; Patrick N Harter; Hans-Georg Wirsching; Marian C Neidert; Miriam Ratliff; Michael Platten; Matija Snuderl; Kenneth D Aldape; Sebastian Brandner; Jürgen Hench; Stephan Frank; Stefan M Pfister; David T W Jones; Guido Reifenberger; Till Acker; Wolfgang Wick; Michael Weller; Matthias Preusser; Andreas von Deimling; Felix Sahm
Journal:  J Clin Oncol       Date:  2021-10-07       Impact factor: 44.544

3.  Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.

Authors:  Victoria E Clark; E Zeynep Erson-Omay; Akdes Serin; Jun Yin; Justin Cotney; Koray Ozduman; Timuçin Avşar; Jie Li; Phillip B Murray; Octavian Henegariu; Saliha Yilmaz; Jennifer Moliterno Günel; Geneive Carrión-Grant; Baran Yilmaz; Conor Grady; Bahattin Tanrikulu; Mehmet Bakircioğlu; Hande Kaymakçalan; Ahmet Okay Caglayan; Leman Sencar; Emre Ceyhun; A Fatih Atik; Yaşar Bayri; Hanwen Bai; Luis E Kolb; Ryan M Hebert; S Bulent Omay; Ketu Mishra-Gorur; Murim Choi; John D Overton; Eric C Holland; Shrikant Mane; Matthew W State; Kaya Bilgüvar; Joachim M Baehring; Philip H Gutin; Joseph M Piepmeier; Alexander Vortmeyer; Cameron W Brennan; M Necmettin Pamir; Türker Kiliç; Richard P Lifton; James P Noonan; Katsuhito Yasuno; Murat Günel
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

4.  TERT Promoter Mutations and Risk of Recurrence in Meningioma.

Authors:  Felix Sahm; Daniel Schrimpf; Adriana Olar; Christian Koelsche; David Reuss; Juliane Bissel; Annekathrin Kratz; David Capper; Sebastian Schefzyk; Thomas Hielscher; Qianghu Wang; Erik P Sulman; Sebastian Adeberg; Arend Koch; Ali Fuat Okuducu; Stefanie Brehmer; Jens Schittenhelm; Albert Becker; Benjamin Brokinkel; Melissa Schmidt; Theresa Ull; Konstantinos Gousias; Almuth Friederike Kessler; Katrin Lamszus; Jürgen Debus; Christian Mawrin; Yoo-Jin Kim; Matthias Simon; Ralf Ketter; Werner Paulus; Kenneth D Aldape; Christel Herold-Mende; Andreas von Deimling
Journal:  J Natl Cancer Inst       Date:  2015-12-13       Impact factor: 13.506

5.  DNA methylation-based classification of central nervous system tumours.

Authors:  David Capper; David T W Jones; Martin Sill; Volker Hovestadt; Daniel Schrimpf; Dominik Sturm; Christian Koelsche; Felix Sahm; Lukas Chavez; David E Reuss; Annekathrin Kratz; Annika K Wefers; Kristin Huang; Kristian W Pajtler; Leonille Schweizer; Damian Stichel; Adriana Olar; Nils W Engel; Kerstin Lindenberg; Patrick N Harter; Anne K Braczynski; Karl H Plate; Hildegard Dohmen; Boyan K Garvalov; Roland Coras; Annett Hölsken; Ekkehard Hewer; Melanie Bewerunge-Hudler; Matthias Schick; Roger Fischer; Rudi Beschorner; Jens Schittenhelm; Ori Staszewski; Khalida Wani; Pascale Varlet; Melanie Pages; Petra Temming; Dietmar Lohmann; Florian Selt; Hendrik Witt; Till Milde; Olaf Witt; Eleonora Aronica; Felice Giangaspero; Elisabeth Rushing; Wolfram Scheurlen; Christoph Geisenberger; Fausto J Rodriguez; Albert Becker; Matthias Preusser; Christine Haberler; Rolf Bjerkvig; Jane Cryan; Michael Farrell; Martina Deckert; Jürgen Hench; Stephan Frank; Jonathan Serrano; Kasthuri Kannan; Aristotelis Tsirigos; Wolfgang Brück; Silvia Hofer; Stefanie Brehmer; Marcel Seiz-Rosenhagen; Daniel Hänggi; Volkmar Hans; Stephanie Rozsnoki; Jordan R Hansford; Patricia Kohlhof; Bjarne W Kristensen; Matt Lechner; Beatriz Lopes; Christian Mawrin; Ralf Ketter; Andreas Kulozik; Ziad Khatib; Frank Heppner; Arend Koch; Anne Jouvet; Catherine Keohane; Helmut Mühleisen; Wolf Mueller; Ute Pohl; Marco Prinz; Axel Benner; Marc Zapatka; Nicholas G Gottardo; Pablo Hernáiz Driever; Christof M Kramm; Hermann L Müller; Stefan Rutkowski; Katja von Hoff; Michael C Frühwald; Astrid Gnekow; Gudrun Fleischhack; Stephan Tippelt; Gabriele Calaminus; Camelia-Maria Monoranu; Arie Perry; Chris Jones; Thomas S Jacques; Bernhard Radlwimmer; Marco Gessi; Torsten Pietsch; Johannes Schramm; Gabriele Schackert; Manfred Westphal; Guido Reifenberger; Pieter Wesseling; Michael Weller; Vincent Peter Collins; Ingmar Blümcke; Martin Bendszus; Jürgen Debus; Annie Huang; Nada Jabado; Paul A Northcott; Werner Paulus; Amar Gajjar; Giles W Robinson; Michael D Taylor; Zane Jaunmuktane; Marina Ryzhova; Michael Platten; Andreas Unterberg; Wolfgang Wick; Matthias A Karajannis; Michel Mittelbronn; Till Acker; Christian Hartmann; Kenneth Aldape; Ulrich Schüller; Rolf Buslei; Peter Lichter; Marcel Kool; Christel Herold-Mende; David W Ellison; Martin Hasselblatt; Matija Snuderl; Sebastian Brandner; Andrey Korshunov; Andreas von Deimling; Stefan M Pfister
Journal:  Nature       Date:  2018-03-14       Impact factor: 49.962

Review 6.  A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.

Authors:  Christian Mawrin; Ralf Koch; Natalie Waldt; I Erol Sandalcioglu; Werner E K Braunsdorf; Jan-Peter Warnke; Felix Goehre; Hans-Jürgen Meisel; Christian Ewald; Sina Neyazi; Ulrich Schüller; Elmar Kirches
Journal:  Brain Pathol       Date:  2022-03       Impact factor: 7.611

7.  Two predominant molecular subtypes of spinal meningioma: thoracic NF2-mutant tumors strongly associated with female sex, and cervical AKT1-mutant tumors originating ventral to the spinal cord.

Authors:  Lingyang Hua; Majd Alkhatib; Dino Podlesek; Leila Günther; Thomas Pinzer; Matthias Meinhardt; Silke Zeugner; Sylvia Herold; Daniel P Cahill; Priscilla K Brastianos; Erik A Williams; Victoria E Clark; Ganesh M Shankar; Hiroaki Wakimoto; Leihao Ren; Jiawei Chen; Ye Gong; Gabriele Schackert; Tareq A Juratli
Journal:  Acta Neuropathol       Date:  2022-08-09       Impact factor: 15.887

8.  Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.

Authors:  Priscilla K Brastianos; Peleg M Horowitz; Sandro Santagata; Robert T Jones; Aaron McKenna; Gad Getz; Keith L Ligon; Emanuele Palescandolo; Paul Van Hummelen; Matthew D Ducar; Alina Raza; Ashwini Sunkavalli; Laura E Macconaill; Anat O Stemmer-Rachamimov; David N Louis; William C Hahn; Ian F Dunn; Rameen Beroukhim
Journal:  Nat Genet       Date:  2013-01-20       Impact factor: 38.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.